Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - PROGRESS UPDATE ON THE LICENSE AGREEMENT ENTERED INTO BY A SUBSIDIARY（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take

no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

PROGRESS UPDATE ON THE LICENSE AGREEMENT ENTERED INTO

BY A SUBSIDIARY

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on a voluntary basis.

References are made to the overseas regulatory announcements of the Company dated 15 March 2020 and 12 November 2020, the announcements of the Company dated 10 November 2020 and 16 December 2020 (the "Announcements") in relation to, among others, the entering in to the License Agreement and the Amendment No.1 between Fosun Pharmaceutical Industrial and BioNTech, pursuant to which BioNTech granted Fosun Pharmaceutical Industrial a license to exclusively develop and commercialise its COVID-19 Vaccine developed based on BioNTech's proprietary mRNA technology platform targeting COVID-19 in the Territory. Unless the context otherwise specified, capitalised terms used herein shall have the same meaning ascribed to them in the Announcements.

The Board is pleased to announce that, according to the press release of the Government of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong"), the Secretary for Food and Health authorised the emergency use of COVID-19 Vaccine, namely BNT162b2 (the "Vaccine") in Hong Kong, with effect from 25 January 2021 (the "Authorisation").

The Company wishes to remind shareholders and potential investors of the Company that, the Authorisation is made in accordance with the Prevention and Control of Disease (Use of Vaccines) Regulation of Hong Kong (Chapter 599K) (the "Regulation"), pursuant to which, the emergency use authorisation is applicable to supply, distribution and use of the COVID-19 vaccine under the vaccination programme of Hong Kong government and circumstances of prevention of transmission of certain disease specified by the Secretary for Food and Health. The valid period of the Authorisation is 12 months after the date of the Authorisation and the Authorisation could be further extended or revoked in accordance with the Regulation. The sale and supply of the Vaccine in Hong Kong is still subject to, among others, the development of the epidemic, the progress of the government's vaccination programme and production and/or supply chain capabilities after the

1

receipt of Authorisation. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, PRC

25 January 2021

As at the date of this announcement, the executive Director of the Company is Mr. Wu Yifang; the non- executive Directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive Directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

2